Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Mult Scler ; 20(11): 1502-10, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24687807

ABSTRACT

BACKGROUND: Approximately one-third of those with pediatric-onset multiple sclerosis (MS) experience cognitive impairment. Less is known concerning their change in cognitive functioning over time. OBJECTIVE: Changes in cognitive function over time were measured in the largest pediatric cohort to date through the US Network of Pediatric MS Centers. METHODS: A total of 67 individuals with pediatric MS (n=62) or clinically isolated syndrome (CIS, n=5), ranging from 8-17 years of age (mean age ± standard deviation (SD)=14.37 ± 2.02) completed initial and follow-up neuropsychological testing after an average of 1.64 ± 0.63 years apart. The nine tests administered measure general intellect, attention and working memory, verbal memory, visuomotor integration, language, and executive functioning. RESULTS: Rate of impairment (having one-third or more scores in the impaired range) was 37% at baseline and 33% at follow-up. Tests commonly impaired were measures of visuomotor integration, speeded processing, and attention. Most tested did not decline over two years. There was no clear pattern of change on any specific measure. CONCLUSION: Findings suggest that, over short timeframes, stable or even improved performances on measures of cognitive ability can occur. Pediatric MS may instead prevent expected age-related cognitive gains.


Subject(s)
Attention/physiology , Cognition Disorders/physiopathology , Multiple Sclerosis/physiopathology , Neuropsychological Tests , Adolescent , Child , Cognition/physiology , Cognition Disorders/etiology , Cognition Disorders/psychology , Executive Function/physiology , Female , Humans , Language , Longitudinal Studies , Male , Memory, Short-Term/physiology , Multiple Sclerosis/complications , Multiple Sclerosis/psychology , United States
2.
Neurology ; 71(2): 93-100, 2008 Jul 08.
Article in English | MEDLINE | ID: mdl-18509092

ABSTRACT

BACKGROUND: In adult patients, autoantibodies targeting the water channel aquaporin-4 (AQP4) are a biomarker for a spectrum of CNS inflammatory demyelinating disorders with predilection for optic nerves and spinal cord (neuromyelitis optica [NMO]). Here we describe the neurologic, serologic, and radiographic findings associated with CNS AQP4 autoimmunity in childhood. METHODS: A total of 88 consecutive seropositive children were identified through service evaluation for NMO-IgG. Sera of 75 were tested for coexisting autoantibodies. Clinical information was available for 58. RESULTS: Forty-two patients (73%) were non-Caucasian, and 20 (34%) had African ethnicity. Median age at symptom onset was 12 years (range 4-18). Fifty-seven (98%) had attacks of either optic neuritis (n = 48; 83%) or transverse myelitis (n = 45; 78%), or both. Twenty-six (45%) had episodic cerebral symptoms (encephalopathy, ophthalmoparesis, ataxia, seizures, intractable vomiting, or hiccups). Thirty-eight (68%) had brain MRI abnormalities, predominantly involving periventricular areas (in descending order of frequency): the medulla, supratentorial and infratentorial white matter, midbrain, cerebellum, thalamus, and hypothalamus. Additional autoantibodies were detected in 57 of 75 patients (76%), and 16 of 38 (42%) had a coexisting autoimmune disorder recorded (systemic lupus erythematosus, Sjögren syndrome, juvenile rheumatoid arthritis, Graves disease). Attacks were recurrent in 54 patients (93%; median follow-up, 12 months). Forty-three of 48 patients (90%) had residual disability: 26 (54%) visual impairment and 21 (44%) motor deficits (median Expanded Disability Status Scale 4.0 at 12 months). CONCLUSIONS: Aquaporin-4 autoimmunity is a distinctive recurrent and widespread inflammatory CNS disease in children.


Subject(s)
Aquaporin 4/immunology , Autoantibodies/analysis , Myelitis, Transverse/immunology , Neuromyelitis Optica/immunology , Adolescent , Autoimmunity , Biomarkers/analysis , Brain/pathology , Child , Child, Preschool , Female , Humans , Magnetic Resonance Imaging , Male , Methylprednisolone/therapeutic use , Myelitis, Transverse/diagnosis , Myelitis, Transverse/drug therapy , Neuromyelitis Optica/diagnosis , Neuromyelitis Optica/drug therapy , Recurrence , Serologic Tests
3.
Neurology ; 68(16 Suppl 2): S37-45, 2007 Apr 17.
Article in English | MEDLINE | ID: mdl-17438237

ABSTRACT

There is increasing appreciation that multiple sclerosis (MS) can begin in childhood or adolescence, but pediatric MS continues to be a rare entity, with an estimated 2 to 5% of patients with MS experiencing their first clinical symptoms before age 16. A prompt diagnosis of pediatric MS is important to optimize overall management of both the physical and social impact of the disease. The widespread use of disease-modifying therapies (DMT) for MS in adults, as early as following an initial isolated episode, has led to the use of DMT in children and adolescents with MS. However, it is imperative to distinguish pediatric MS from other childhood CNS inflammatory demyelinating disorders such as acute disseminated encephalomyelitis. Although increasing evidence suggests a slower disease course in children with MS compared to adults, significant disability can still accumulate by early adulthood. Furthermore, associated neurocognitive deficits can impair both academic and psychosocial function at a critical juncture in a young person's life. This article reviews the clinical characteristics, neuroimaging, paraclinical findings, disease course, epidemiology, genetics, and pathophysiology of pediatric MS vis-à-vis adult MS. Further research of pediatric MS may advance our understanding of MS pathophysiology in general, as well as improve the long-term health care outcomes of children and adolescents diagnosed with MS.


Subject(s)
Multiple Sclerosis , Adolescent , Adult , Child , Disease Progression , Humans , Magnetic Resonance Imaging , Multiple Sclerosis/diagnosis , Multiple Sclerosis/pathology , Multiple Sclerosis/physiopathology , Multiple Sclerosis/therapy , Prognosis , Treatment Outcome
4.
Neurology ; 68(16 Suppl 2): S46-53, 2007 Apr 17.
Article in English | MEDLINE | ID: mdl-17438238

ABSTRACT

BACKGROUND: MRI has revolutionized the diagnostic accuracy of multiple sclerosis (MS) in adults, and is now used extensively to evaluate efficacy of immunomodulatory therapies. Although MRI has also been used to aid in the diagnosis and care of children with MS, the MRI features of MS in children are less well understood. METHODS: The present review summarizes the available literature on MRI in pediatric MS, outlines the specific features of other disorders affecting the CNS white matter in children, compares the MRI appearance of MS in children to seminal neuroimaging studies in adult-onset MS, and discusses the potential role of advanced MRI technologies in delineating the underlying pathobiology of acquired demyelinating disease in children. RESULTS: Although the MRI features of MS in children have similarity to adult-onset MS, children tend to have fewer lesions and a lower propensity for lesions to enhance with gadolinium. The MRI findings in children presenting with a clinical phenotype of acute disseminated encephalomyelitis may be indistinguishable from the first attack of MS. CONCLUSIONS: MRI criteria specific for pediatric-onset multiple sclerosis (MS) and criteria predictive of MS outcome in children experiencing a first demyelinating event will be challenged by the overlap in MRI features between acute monophasic demyelinating syndromes and MS, particularly in younger children. Emergence of new clinically silent lesions on MRI scans separated by at least 3 months is characteristic of MS. Newer MRI techniques evaluating white matter biochemistry and integrity in the youngest MS patients may provide new insights into the relative contributions of inflammation and neurodegeneration in MS.


Subject(s)
Magnetic Resonance Imaging , Multiple Sclerosis/diagnosis , Multiple Sclerosis/pathology , Adult , Central Nervous System Diseases/diagnosis , Central Nervous System Diseases/pathology , Child , Contrast Media/metabolism , Encephalomyelitis, Acute Disseminated/diagnosis , Encephalomyelitis, Acute Disseminated/pathology , Gadolinium/metabolism , Humans , Multiple Sclerosis/physiopathology , Nerve Fibers, Myelinated/pathology , Pediatrics , Predictive Value of Tests , Prognosis
5.
J Reprod Fertil ; 105(1): 125-33, 1995 Sep.
Article in English | MEDLINE | ID: mdl-7490703

ABSTRACT

Concanavalin A-stimulated splenocytes secrete a factor that stimulates progesterone production in cultured rat granulosa cells. The actions of this progesterone-stimulating factor (PSF) were characterized further by purifying it by sequential chromatographies on heparin-agarose, copper chelating-Sepharose and Mono S columns. Several of its effects on granulosa cells were then compared with those of FSH. Like FSH, PSF induced accumulation of progesterone and 20 alpha-dihydroprogesterone in granulosa cell culture media; however, the time course of progesterone accumulation in response to PSF was much slower than that in response to FSH. In contrast to FSH, PSF induced little accumulation of oestrogen. Induction of other differentiated responses was compared by pretreating cultured granulosa cells with either FSH or PSF, and then challenging with LH, prolactin, epidermal growth factor or the beta-adrenergic agonist, isoproterenol. Pretreatment with FSH induced subsequent responsiveness to all four agents, whereas pretreatment with PSF induced subsequent responsiveness only to isoproterenol. These results indicate that granulosa cell responses to PSF are much more limited than are those to FSH and that these responses are characterized by an increase in progestin production.


Subject(s)
Concanavalin A/pharmacology , Granulosa Cells/metabolism , Progesterone/biosynthesis , Spleen/chemistry , Animals , Cells, Cultured , Epidermal Growth Factor/pharmacology , Female , Follicle Stimulating Hormone/pharmacology , Granulosa Cells/drug effects , Isoproterenol/pharmacology , Luteinizing Hormone/pharmacology , Prolactin/pharmacology , Rats , Rats, Sprague-Dawley , Spleen/cytology , Stimulation, Chemical
6.
Mol Cell Endocrinol ; 106(1-2): 163-70, 1994 Dec.
Article in English | MEDLINE | ID: mdl-7895903

ABSTRACT

We have previously identified and purified a splenocyte-derived factor (PSF) that stimulates the accumulation of progesterone and 20 alpha-dihydroprogesterone (20 alpha-OH-P) in rat ovarian granulosa cells independently of FSH. In the present study, time course experiments comparing the response to PSF with that to FSH revealed that PSF-stimulated progesterone accumulation was slower than that of FSH, but PSF-stimulated 20 alpha-OH-P accumulation had a time course similar to that of FSH. To determine the basis for the slower progesterone response to PSF, the effect of these two agents on each step of the steroidogenic pathway was assessed. First, to examine whether PSF-stimulated cholesterol mobilization was limiting, cultured granulosa cells were treated with 22(R)-hydroxycholesterol. While both FSH- and PSF-stimulated progesterone and 20 alpha-OH-P accumulation approximately doubled, the overall time courses did not change indicating that cholesterol availability was not the factor limiting the response to PSF. Next, PSF and FSH induction of steroidogenic enzyme activities and messenger RNAs were compared. While FSH-stimulated cytochrome P450 side chain cleavage enzyme (SCC) activity rapidly increased (peaking at 2 days) and then slowly declined, PSF-stimulated SCC activity gradually increased over 5 days to approximately 35% of the maximal activity stimulated by FSH. PSF also induced slower increases in P450scc mRNA levels than did FSH. In addition, PSF stimulated 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) activity more slowly than did FSH, but after 3 days of culture, PSF-stimulated activity was significantly higher than that induced by FSH.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
3-Hydroxysteroid Dehydrogenases/biosynthesis , Cholesterol Side-Chain Cleavage Enzyme/biosynthesis , Granulosa Cells/enzymology , RNA, Messenger/metabolism , Spleen/metabolism , Steroids/biosynthesis , 20-Hydroxysteroid Dehydrogenases/biosynthesis , 20-Hydroxysteroid Dehydrogenases/genetics , 20-alpha-Hydroxysteroid Dehydrogenase , 3-Hydroxysteroid Dehydrogenases/genetics , Animals , Cholesterol Side-Chain Cleavage Enzyme/genetics , Female , Follicle Stimulating Hormone/pharmacology , Kinetics , Male , Rats , Rats, Sprague-Dawley
7.
Mol Cell Endocrinol ; 90(1): 17-25, 1992 Dec.
Article in English | MEDLINE | ID: mdl-1338729

ABSTRACT

c-Fos and c-jun are immediate early proto-oncogenes encoding proteins for the heterodimer AP-1, a DNA binding complex which regulates gene transcription. In order to investigate the presence and potential gonadotropin regulation of mRNAs for these proto-oncogenes in rat granulosa cells, we used Northern blotting of total RNA from cultured cells. Granulosa cells obtained from diethylstilbestrol (DES)-treated weanling rats were challenged with follicle-stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), dibutyryl cAMP ((Bu)2cAMP) or tetradecanoyl-13-phorbol acetate (TPA) either 2.5 h after cell isolation (day 0) or following a 2-day pretreatment with FSH (day 2). Freshly isolated cells treated with FSH exhibited 4-fold and 3-fold increases in c-fos and c-jun mRNAs, respectively, within 30 min. Two hours after FSH treatment, both c-fos and c-jun message levels diminished to near control levels. Granulosa cells pretreated for 2 days with FSH, then re-challenged with FSH, showed similar increases in both c-fos and c-jun messages. These effects were dose- and time-dependent on both day 0 and day 2. Likewise, (Bu)2cAMP also increased c-fos and c-jun mRNAs in a time- and dose-dependent manner on both day 0 and day 2. In contrast, LH or hCG minimally increased c-fos and c-jun mRNAs on day 0, but on day 2, both hormones markedly increased message levels in a manner similar to that seen with FSH. Analogous effects were observed with TPA which minimally stimulated c-fos and c-jun mRNAs on day 0, but markedly increased these messages on day 2. These studies demonstrate that c-fos and c-jun mRNAs can be induced in cultured rat granulosa cells by acute gonadotropin, (Bu)2cAMP or phorbol ester treatment and suggest that these immediate early proto-oncogenes may play a role in granulosa cell function.


Subject(s)
Chorionic Gonadotropin/pharmacology , Follicle Stimulating Hormone/pharmacology , Gene Expression Regulation/drug effects , Genes, fos , Genes, jun , Granulosa Cells/drug effects , Luteinizing Hormone/pharmacology , RNA, Messenger/biosynthesis , Actins/genetics , Animals , Bucladesine/pharmacology , Cells, Cultured , DNA, Recombinant/genetics , Diethylstilbestrol , Female , Granulosa Cells/metabolism , Humans , Rats , Rats, Sprague-Dawley , Sheep , Tetradecanoylphorbol Acetate/pharmacology , Time Factors , Transcription, Genetic/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...